The Russian market of medicines for the therapy of urogenital chlamydiasis

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2020-01-06
Issue: 
1
Year: 
2020

M.D. Mukovnina(1), A.I. Ovod(2), I.G. Komissinskaya(2) 1-N.N. Burdenko Voronezh State Medical University, 10, Studencheskaya St., Voronezh 394036, Russian Federation; 2-Kursk State Medical University, 3, Karl Marx St., Kursk 305041, Russian Federation

Introduction. Due to the population’s high demand for medical care for social diseases, the Russian market of medicines used to treat them was studied. Objective: to analyze the range of drugs for social diseases (for example, those to cure urogenital chlamydiasis). Material and methods. Patient management protocols, clinical guidelines for management, and official sources of information were applied. Logical, systematic analytical, graphical, marketing, and statistical (tabular, graphical) analyses were used. Results. The paper presents the results of analyzing the market of medicines for the treatment of social diseases, such as urogenital chlamydiasis, as of 2018. The investigators revealed the problems of the availability of drugs in ATC groups. The comparative analysis of the range of drugs in 2012 and 2018 showed no dramatic change in the pattern of their range. The number of trade names for the assortment under study increased 2.3-fold (primarily due to Russian manufacturers), which is suggestive of the development of the Russian pharmaceutical industry. Conclusion. The range of drugs for the treatment of urogenital chlamydiasis is under government control: many basic drugs for its therapy are included in the list of essential medicines; this provides government control of pricing and increases their availability for patients. However, there is some dependence on import for individual drugs.
Keywords: 
social diseases
sexually transmitted infections
urogenital chlamydiasis
drugs
References: 
  1. Volodina T.A., Saskova P.V., Ivanova E.V. Urogenital chlamydiosis: current state. Farmatsiya i farmakologiya, 2014; 2 (6–7): 66–73. https://doi.org/10.19163/2307-9266-2014-2-6(7)-66-73 (in Russian).
  2. Malova I.O., Sidorova I.A., Shelomentseva N.N. Urogenital clamidiosis in women of reproductive age: a rational approach to the treatment. Sibirskij Medicinskij Zurnal (Irkutsk), 2013; 117 (2): 46–50 (in Russian).
  3. The global strategy of the health sector on sexually transmitted infections 2016–21. WHO; 2016. [Electronic resource]. Accessmode: http://www.who.int/mediacentre/factsheets/fs110/ru [circulation date 01 December, 2018] (in Russian).
  4. Patel C.G., Trivedi S., Tao G. The Proportion of Young Women Tested for Chlamydia Who Had Urogenital Symptoms in Physician Offices. Sex. Transm. Dis., 2018 Sep; 45 (9): e72–e74. https://doi.org/10.1097/OLQ.0000000000000858
  5. Kubanova A.A., Kubanov A.A., Melekhina L.E.Dynamics of incidence of sexually transmitted infections in the evaluation of the epidemiological process and state of health of the Russian Federation population in 2006–2016. Vestnik Dermatologii i venerologii, 2018; 94 (1): 27–37. https://doi.org/10.25208/0042-4609-2018-94-1-27-37 (in Russian).
  6. Hathorn E., Opie C., Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex.Transm.Infect., 2012; Aug; 88 (5): 352–4. https://doi.org/10.1136/sextrans-2011-050466
  7. Khryanin A.A. Urogenital chlamydia infection in women: patient management tactics according to present-day foreign and Russian recommendations.Vestnik dermatologii i venerologii, 2015; (2): 101–10. https://doi.org/10.25208/0042-4609-2015-0-2-101-110 (in Rusian).
  8. State Register of Medicinal Products of the Russian Federation. [Electronicresource]. Accessmode: https://grls.rosminzdrav.ru/grls.aspx[circulation date 01 September, 2018] (in Russian).